All In Biotech

Drug Trial Radar · NCT05626114

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

A Phase IIa, Multicenter, Open-label, Single-Arm Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 23, 2023

Primary completion

Mar 1, 2031

Study completion Mar 1, 2031

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated. The substudy will evaluate the operational feasibility and scientific interpretability of incorporating AO retinal imaging using the EarlySight Cellularis® Discovery device. Participants who have fulfilled the eligibility requirements for the parent study and meet the substudy's eligibility criteria will have the option to participate in the substudy. The EarlySight Cellularis® Discovery device will be used only as an assessment tool and data obtained from this device will not be used to guide clinical care or influence clinical outcomes for participants.

Conditions

  • Geographic Atrophy

Interventions

  • OpRegenBiological

    OpRegen dose of up to approximately 200,000 cells will be delivered into the subretinal space.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants With Subretinal Surgical Delivery of OpRegen to Target RegionsTime frame: 3 months post-surgery
  2. Incidence and Severity of Procedure-related Adverse Events (AEs) at 3 Months Following SurgeryTime frame: 3 months post-surgery

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California · Recruiting

  • Retinal Consultants Medical Group

    Sacramento, California · Recruiting

  • West Coast Retina

    San Francisco, California · Recruiting

  • Retina Vitreous Associates of Florida

    St. Petersburg, Florida · Recruiting

  • The Retina Care Center

    Baltimore, Maryland · Recruiting

  • The Retina Institute

    St Louis, Missouri · Recruiting

  • Sierra Eye Associates

    Reno, Nevada · Recruiting

  • Duke Eye Center

    Durham, North Carolina · Recruiting

  • Cincinnati Eye Institute

    Blue Ash, Ohio · Recruiting

  • Mid Atlantic Retina

    Philadelphia, Pennsylvania · Recruiting

  • Tennessee Retina PC

    Nashville, Tennessee · Recruiting

  • Austin Clinical Research, LLC

    Austin, Texas · Recruiting

  • Retina Consultants of Texas

    Bellaire, Texas · Recruiting

  • Piedmont Eye Center

    Lynchburg, Virginia · Recruiting

  • Spokane Eye Clinical Research;Spokane Eye Surgery Center

    Spokane, Washington · Recruiting

  • Hadassah MC

    Jerusalem, Israel · Recruiting

  • Tel Aviv Sourasky MC

    Tel Aviv, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.